Current management of the myeloproliferative disorders: a case-based review.

Properly managed, the myeloproliferative disorders are generally compatible with prolonged survival. Challenges to the hematologist include knowing when and how best to intervene to prevent and manage complications. The cytoreductive agent of choice for these disorders is currently hydroxyurea, emerging from randomized trials beginning with those of the Polycythemia Vera Study Group.
To examine the roles and shortcomings of interventions (including hydroxyurea, antiplatelet agents, anagrelide, interferon, thalidomide, alkylating agents, cell cytopheresis, erythropoietins, splenectomy, bone marrow transplantation, and imatinib) for myeloproliferative disorders.
This report uses actual case histories to illustrate the roles and shortcomings of these interventions.
Beyond phlebotomy for polycythemia vera, patients with polycythemia vera and essential thrombocythemia can be stratified by their risk for thrombosis, which guides the institution of cytoreductive therapies. High-risk patients generally benefit from cytoreductive therapy, and hydroxyurea has emerged as the agent of choice, because alkylating agents (and P32) have high leukemogenic potentials. Anagrelide and interferon are second-line agents. The addition of low-dose aspirin is beneficial for most, helping to prevent arterial thrombotic complications. Therapy in any of these disorders should be tailored to the unique characteristics of the individual patient. With myelofibrosis, therapeutic options run the gamut from observation, erythropoietic stimulators, cytotoxic agents, splenectomy, and bone marrow transplantation. Thalidomide and imatinib have shown some utility. Future challenges are the refinement of individualized treatment strategies and the development of targeted therapies based on rapidly expanding understanding of the molecular perturbations in these disorders.
AuthorsLawrence Rice, Kelty R Baker
JournalArchives of pathology & laboratory medicine (Arch Pathol Lab Med) Vol. 130 Issue 8 Pg. 1151-6 (Aug 2006) ISSN: 1543-2165 [Electronic] United States
PMID16879016 (Publication Type: Case Reports, Journal Article, Review)
Chemical References
  • Antineoplastic Agents
  • Platelet Aggregation Inhibitors
  • Adult
  • Antineoplastic Agents (therapeutic use)
  • Female
  • Humans
  • Middle Aged
  • Phlebotomy
  • Platelet Aggregation Inhibitors (therapeutic use)
  • Polycythemia Vera (pathology, therapy)
  • Primary Myelofibrosis (complications, pathology, therapy)
  • Thrombocythemia, Essential (drug therapy, pathology)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: